Epidemiological studies have demonstrated conflicting effects of RAS inhibition in cancer [80], with studies showing no significant difference with ACE inhibitor or angiotensin receptor blocker use [80], although a more recent clinical trial investigating the neoadjuvant use of losartan demonstrates downstaging in pancreatic cancer [81]. Here, ACE is linked to pancreatic neoplasm.